Effect of weight loss on proteinuria in adults with type 2 diabetes: A real-world study

被引:2
|
作者
Ren, Wenqian [1 ]
Gong, Yujia [1 ]
Zhen, Qin [1 ]
Gu, Liping [1 ]
Yang, Jiaying [1 ]
Kang, Mei [2 ]
Zhang, Aifang [1 ]
Shen, Tingting [1 ]
Wang, Yufan [1 ]
Liu, Fang [1 ,3 ]
Li, Na [1 ,3 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Endocrinol & Metab, Shanghai 200080, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Clin Med Res Ctr, Sch Med, Shanghai 200080, Peoples R China
[3] 100 Haining Rd, Shanghai 200080, Peoples R China
基金
中国国家自然科学基金;
关键词
Body weight; Proteinuria; Regression; Type; 2; diabetes; CHRONIC KIDNEY-DISEASE; BODY-MASS INDEX; RISK-FACTORS; OBESITY; PREVALENCE; MANAGEMENT;
D O I
10.1016/j.diabres.2023.111021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To assess the impact of weight loss on proteinuria in patients with type 2 diabetes (T2DM) in real-world settings. Methods: A total of 1054 participants were categorized based on weight change from baseline to one-year followup: weight gain (>= 3%), stable weight, or weight loss (>= 3%). Proteinuria outcomes were defined as urinary albumin/creatinine ratio (UACR) progression (>= 30 % increase), UACR regression (>= 30 % reduction), or UACR stable. Ordered logistic regression analysis evaluated the relationship between weight loss and UACR regression. Results: Of the 1054 participants, 44.5 % were overweight, and 24.1 % were obese. Patients with obesity were at higher risk of developing proteinuria (OR, 1.783; 95 %CI, 1.195 to 2.659). Weight loss was associated with an 83.3 % increase in UACR regression compared to weight gain (OR, 1.833; 95 % CI, 1.262 to 2.663; P = 0.001). This association remained consistent across most subgroups and stronger in males (P for interaction = 0.023), with a 6 % UACR regression for every 1 kg weight loss (OR, 1.06; 95 % CI, 1.02 to 1.10; P = 0.003). Conclusions: Our real-world study reveals that weight reduction is associated with UACR regression in patients with T2DM, regardless of the approach used for weight management, and the association was much stronger in males.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes
    Manti, Roberta
    De Cosmo, Salvatore
    Desenzani, Paolo
    Ferrara, Lidia
    Girelli, Angela
    Memoli, Giuseppe
    Bisio, Alessandro
    Braae, Uffe Christian
    Deinega, Alisa
    Berra, Cesare
    PIONEER REAL Italy Investigators, Massimiliano
    DIABETES THERAPY, 2025, : 1019 - 1032
  • [33] Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a real-world database
    Kwon, Jimmy
    Thiara, Diana
    Watanabe, Jonathan H.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2025, 20 (02) : 163 - 168
  • [34] Real-world evidence of characteristics and factors influencing herbal medicine use for weight loss in adults
    Lee, Boram
    Yang, Changsop
    Yim, Mi Hong
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [35] A real-world observational study on the effect of Qingre Lishi decoction on glycemic profile using continuous glucose monitoring in obese type 2 diabetes adults
    Wei, Bingchen
    Gao, Tianshu
    Li, Mingzhe
    Tian, Xiaojun
    Wang, Jinxi
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [36] Treatment Patterns and Glycaemic Control Between 2015 and 2019 in Tianjin, China: A Real-World Study of Adults with Type 2 Diabetes
    Zhang, Qiumei
    Fan, Yaqing
    Liu, Xixi
    Zhang, Minlu
    Zhang, Jiewen
    Du, Qin
    Kang, Lei
    Chen, Liming
    DIABETES THERAPY, 2025, 16 (01) : 1 - 14
  • [37] Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study
    Sándor Szépkúti
    Szilvia Bandur
    Gábor Kovács
    Tamás Ferenci
    Márk M. Svébis
    Piroska Turbucz
    Ádám G. Tabák
    BMC Endocrine Disorders, 22
  • [38] Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study
    Szepkuti, Sandor
    Bandur, Szilvia
    Kovacs, Gabor
    Ferenci, Tamas
    Svebis, Mark M.
    Turbucz, Piroska
    Tabak, Adam G.
    BMC ENDOCRINE DISORDERS, 2022, 22 (01)
  • [39] Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: A retrospective cohort study
    White, Gretchen E.
    Shu, Ingrid
    Rometo, David
    Arnold, Jon
    Korytkowski, Mary
    Luo, Jing
    OBESITY, 2023, 31 (02) : 537 - 544
  • [40] Long-Term Treatment with Testosterone Leads to Profound Weight Loss in Men with Hypogonadism and Type 2 Diabetes: Update of Real-World Data from a Registry Study
    Haider, Ahmad
    Haider, Karim S.
    Saad, Farid
    DIABETES, 2022, 71